Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
 
(16 intermediate revisions by 2 users not shown)
Line 1: Line 1:
== What are the 10 biggest for-profit companies in this field?==
{{TOCright}}


''Note on outputs: all these companies make their money primarily through developing and patenting drugs. The distinguishing factor seems to be that the largest of these companies produce the drugs themselves, while the smaller ones license these drugs to be produced by larger pharmaceutical companies''
=Introduction=


{| border=1 class="prettytable"
The US biotechnology industry includes about 1,000 companies, with combined annual revenue close to $50 billion. Large companies include [http://www.amgen.com/ Amgen], [http://www.monsanto.com/ Monsanto], [http://www.gene.com/gene/index.jsp Genentech], and [http://www.biogenidec.com/ Biogen]. The biotechnology and the pharmaceutical industries overlap considerably, since many drugs are now developed using biotechnology. The industry consists of a few very large companies and many very small ones, and is fragmented by type of product. Most companies have annual sales under $50 million. 
|
| '''2006 Revenue ($m)'''
| '''Headquarters'''
| '''Primary Outputs'''
| '''Instances of Commons-based approaches'''


|-
Industry overview here: [http://bio.org/speeches/pubs/er/statistics.asp Biotechnology Industry Organization]
| Amgen
| <div align="center">14268</div>
| Thousand Oaks, California
| ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
| Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed


|-
Key Industry Statistics
| Genentech
Key Industry Figures 2008
* Industry Revenue: 85,695.4$Mil
* Revenue Growth: 12.9%
* Industry Gross Product: 58,539.2 $Mil
* Number of Establishments: 6,815 Units
* Number of Enterprises: 6,480 Units
* Employment: 341,000 Units
* Exports: 7,251$Mil
* Imports: 2,954.7$Mil
* Total Wages: *20,630.9$Mil
Source: [http://www.ibisworld.com/industry/retail.aspx?indid=2001&chid=1 Ibis World]


=[[BGP Company Profiles]]=
=[[Publishing Companies with focus on BGP]]=


 
=Navigation=
| <div align="center">9284</div>
* [[Bibliography for Item 6 in BGP]]<br>
 
* [[Biotechnology_-_Genomic_and_Proteomics]]
 
 
| South San Francisco
 
 
 
| synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process
| ?
 
|-
| Genzyme
 
 
 
| <div align="center">3187</div>
 
 
 
| Cambridge, Massachusetts
 
 
 
| Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue
| ?
 
|-
| Gilead Sciences
 
 
 
| <div align="center">3026</div>
 
 
 
| Foster City, California
| 11 commercial products
 
 
 
| ?
 
|-
| Biogen Idec
 
 
 
| <div align="center">2683</div>
 
 
 
| Cambridge, Massachusetts
 
 
 
| Treatments for Crohn's disease, non-Hodgkin's lymphoma, and multiple sclerosis
| Biogen outsources analyzing clinical trial data to other research labs (Powell pp. 72). Perhaps some of these exhibit commons-like behavior
 
|-
| Cephalon
 
 
 
| <div align="center">1764</div>
 
 
 
| Frazer, Pennsylvania
| Specializes in treating neurodegenerative diseases
| ?
 
|-
| MedImmune
 
 
 
| <div align="center">1277</div>
 
 
 
| Gaithersburg, Maryland
| Only major drug prevents respiratory diseases in infants
| ?
 
|-
| Celgene
 
 
 
| <div align="center">899</div>
 
 
 
| Summit, New Jersey
 
 
 
| treatments for erythema nodosum leprosum ("ENL") and multiple myeloma
| ?
 
|-
| Abraxis BioScience
 
 
 
| <div align="center">766</div>
 
 
 
| Los Angeles, California
 
 
 
| uses patented nanoparticle technology to produce products for metastatic breast cancer
| ?
 
|-
| ImClone Systems
 
 
 
| <div align="center">678</div>
 
 
 
| New York, New York
 
 
 
| acquired by Eli Lilly, tried to produce Erbitux for Colorectal Cancer, but failed to win FDA approval
| ?
 
|}
==How is the market distributed?==
==Are there any incentives for specific locations?==
 
==Correlate them with their main outputs (Data. Narratives. Tools)==
 
===[[BGP Company Profiles - Data]]===
 
[http://www.nih.gov/ NIH]
 
[https://www.celera.com/ Celera]
 
Amgen
 
Genentech
 
Genzyme
 
Gilead Sciences
 
Biogen Idec
 
Cephalon
 
MedImmune
 
Celgene
 
Abraxis BioScience
 
ImClone Systems
 
===[[BGP Company Profiles - Narratives]]===
 
[http://www.elsevier.com/wps/find/homepage.cws_home Elsevier]
 
[http://www.ncbi.nlm.nih.gov/pubmed/ PubMed]
 
[http://www.nature.com/ Nature]
 
[http://www.springer.com Springer]
 
[http://www.biomedcentral.com/ BioMedCentral]
 
===[[BGP Company Profiles - Tools]]===
<br>
 
 
==Navigation==
[[Bibliography for Item 6 in BGP]]<br>
[[Biotechnology_-_Genomic_and_Proteomics]]

Latest revision as of 19:40, 22 April 2010

Introduction

The US biotechnology industry includes about 1,000 companies, with combined annual revenue close to $50 billion. Large companies include Amgen, Monsanto, Genentech, and Biogen. The biotechnology and the pharmaceutical industries overlap considerably, since many drugs are now developed using biotechnology. The industry consists of a few very large companies and many very small ones, and is fragmented by type of product. Most companies have annual sales under $50 million.

Industry overview here: Biotechnology Industry Organization

Key Industry Statistics Key Industry Figures 2008

  • Industry Revenue: 85,695.4$Mil
  • Revenue Growth: 12.9%
  • Industry Gross Product: 58,539.2 $Mil
  • Number of Establishments: 6,815 Units
  • Number of Enterprises: 6,480 Units
  • Employment: 341,000 Units
  • Exports: 7,251$Mil
  • Imports: 2,954.7$Mil
  • Total Wages: *20,630.9$Mil

Source: Ibis World

BGP Company Profiles

Publishing Companies with focus on BGP

Navigation

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Biotechnology_-_Genomic_and_Proteomics/IP_Profile_of_Biggest_for-profit_companies_in_BGP&oldid=6898"